Company Profile
What's New
Product Information
Applications Info
Tech Reference List
Information Request
Contact Us
Careers
Email Newsletter
Frequently Asked Questions
In Vitro Basics
In Vitro Toxicology Testing (Non-Animal Safety Testing)
Nanoparticle Research Using MatTek Human Tissue Constructs
Site Map
Search




MatTek Corporation
200 Homer Avenue
Ashland, MA  01721
508-881-6771
FAX:  508-879-1532
E-mail Us

Reproducibility Guaranteed!
Front page
Search

Category: Technical References, MelanoDerm

500. IDENTIFICATION OF QUINOLINES THAT INHIBIT MELANOGENESIS BY ALTERING TYROSINASE FAMILY TRAFFICKING.


Ni-Komatsu, L., Tong, C., Chen, G., Brindzei, N., and Orlow, S.J. The Ronald O. Perelman Department of Dermatology and the Department of Cell Biology, New York University School of Medicine, New York, New York (L.N.-K., C.X.T., N.B., S.J.O.); and PTC Therapeutics, South Plainfield, New Jersey (G.C.). Mol Pharmacol, 74, 1576-1586, (2008).

Summary:
This study by scientists at the New York University School of Medicine and PTC Therapeutics demonstrated how MatTek's MelanoDerm in vitro human skin tissue equivalent can be used to measure the depigmenting effects of human skin lightening agents.

A series of quinolines, including chloroquine and quinine, were identified as potent pigmentation inhibitors through screening a compound library in murine melanocytes. Structure-activity relationship analysis indicated that 4-substituted amino groups with a tertiary amine side chain, such as chloroquine, were associated with robust inhibitory activity.

In contrast to many previously identified pigmentation inhibitors, these newly identified inhibitors had no effect on either the level or the enzymatic activity of tyrosinase, the rate-limiting enzyme in melanin production. Rather, these results showed that these quinolines inhibited melanogenesis by disrupting the intracellular trafficking of tyrosinase-related proteins and lysosome-associated membrane protein 1 (Lamp-1).

In treated melanocytes, tyrosinase and tyrosinase-related protein 1 accumulated in Lamp-1- positive perinuclear organelles instead of melanosomes, thus preventing melanogenesis.

The depigmenting abilities of chloroquine and quinine salicylate were assessed in a human skin equivalent model (MelanoDerm). Both compounds were considerably more effective than arbutin, a widely used lightening agent.

These results indicate that quinolines may be useful agents for “cosmeceutical” skin lightening and treatment of hyperpigmentation disorders.

====================

Request an Electronic Copy (PDF format) of this Technical Paper

====================

MelanoDerm Data Sheet

MelanoDerm Technical Specifications

MelanoDerm Technical References


Applications: Cosmeceuticals, Melanogenesis, Skin lightening/whitening, Skin pigmentation

Keywords: Cosmeceuticals, EPI-100-NMM-113, Fontana-Masson silver stain, Intracellular trafficking, Lysome-associated membrane protein 1, MEL-300-A, MEL-300-B, MTT, MTT assay, Melanin content, MelanoDerm, Spectrum collection, Top view microscopy, Tyrosinase-related proteins

Materials Tested: Arbutin, Chloroquine, Quinine salicylate, Water/PEG (30:70)



Top